In T2D with ASCVD/high CV risk, SGLT2i reduced the kidney composite outcome when compared to incretin-based therapies (HR 0.84, 95% CI 0.73–0.96) and finerenone (HR 0.78, 95% CI 0.65–0.94), with no significant difference between incretin-based therapies and finerenone (HR 0.93, 95% CI 0.78–1.11). This evidence concerns the gene GCG and atherosclerosis.